IL-ZS
28.7.2021 15:02:04 CEST | Business Wire | Press release
Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/
Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about.
Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global pharmaceuticals and biotechnology practice for nearly a decade, driving growth and market penetration across both established and emerging companies. While heading up the firm’s advanced data science track, he and 250 data scientists helped integrate AI-enabled solutions across many business areas. He’s recently turned his attention to expanding the firm’s healthcare expertise to help clients establish deeper relationships and more effective partnerships across the healthcare ecosystem to improve health outcomes, emphasize a better patient experience and address health disparities.
“Pratap is stepping into this role during an exciting period of growth and change at ZS,” said Wright, who oversaw the company’s 30% growth in 2020. “We’re increasingly being called in by the companies we partner with to identify, advise on and adapt to the next big shifts in their respective industries. I’m confident that under Pratap’s counsel, the best days at ZS are ahead of us.”
“Chris has done a tremendous job during his tenure as CEO, and I’ll be leaning on his knowledge and guidance in the months and years ahead,” Khedkar said. “His greatest legacy is preserving the culture that our founders worked so hard to create. His emphasis on continually investing in our people has ‘kept the magic alive,’ as he’s been known to say.”
Khedkar will oversee the global acceleration and scaling of ZS’s portfolio of life sciences and healthcare work. He plans to ramp up investments in the firm’s technology, digital analytics and software capabilities across healthcare and in other industries. To continue working alongside clients and staying connected to market trends, Khedkar is making a critical adjustment to the leadership operating model by appointing 20-year ZS veteran Sandra Forero to the firm’s newly created chief operating officer role.
Forero has held various leadership positions at ZS, including client service lead for two major biopharma clients, head of the firm’s integrated analytics practice, founding chair of the people and culture team, chair of the inclusion and diversity council and elected member of ZS’s shareholder’s council since 2015.
“I welcome Sandra to this role and look forward to partnering with her. She’s a trusted and respected leader at ZS who is incredibly passionate about driving client impact, ensuring the growth and success of our people and stewarding our culture,” Khedkar said. “Our commitment to excellence and solving complex problems is critical for both personal and firm growth and has made ZS what it is today. And, we’re strongly positioned to continue doing more of what ZS does best: helping companies and their customers thrive.”
“At ZS, we work together to leverage our deep expertise in industry and functional areas, analytics and technology to cultivate a culture of innovation and collaboration for client benefit,” said Jaideep Bajaj, chairman of the board at ZS. He held the position of CEO from 2003 to 2012. “I’m excited about ZS’s next era with Pratap leading a strong team that’s focused on creating value for our clients.”
Khedkar holds a Ph.D. in artificial intelligence from the University of California, Berkeley and a Bachelor of Technology degree in computer science from the Indian Institute of Technology Delhi.
About ZS
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 10,000-plus ZSers in 28 offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005232/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release
Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
